Table 7.
S. no | Phytocomponents | Lipophilicity (consensus Log Po/w) | BBB permeant | P-gp substrate | CYP1A2 inhibitor | CYP2C19 inhibitor | CYP2C9 inhibitor | CYP2D6 inhibitor | CYP3A4 inhibitor | Log Kp (skin permeation) | GI absorption |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | N-(3-Aminopropyl)morpholine | 0.15 | No | No | No | No | No | No | No | − 7.67 | High |
2 | 2-Benzylpiperidine | 2.60 | Yes | No | No | No | No | Yes | No | − 5.48 | High |
3 | Guanosine | − 2.02 | No | No | No | No | No | No | No | − 9.37 | Low |
4 | Hexatriacontane | 13.67 | No | Yes | No | No | No | No | No | 4.18 | Low |
5 | 2,8-dimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol | 7.58 | No | Yes | No | No | No | No | No | − 1.68 | Low |
6 | Beta-Tocopherol | 7.79 | No | Yes | No | No | No | No | No | − 1.51 | Low |
7 | Gamma-Tocopherol | 7.95 | No | Yes | No | No | No | No | No | − 1.51 | Low |
8 | Campesterol | 6.90 | No | No | No | No | No | No | No | − 2.50 | Low |
9 | dl-alpha-Tocopherol | 8.27 | No | Yes | No | No | No | No | No | − 1.33 | Low |
10 | Stigmasta-5,22-dien-3-ol, (3.beta.,22e)- | 6.97 | No | Yes | No | No | Yes | No | No | − 2.74 | Low |
11 | Beta-Sitosterol | 7.19 | No | No | No | No | No | No | No | − 2.20 | Low |
12 | Fucosterol | 7.07 | No | No | No | No | No | No | No | − 2.53 | Low |
13 | Lupeol | 7.26 | No | No | No | No | No | No | No | − 1.90 | Low |
14 | Hexacosane | 10.09 | No | Yes | No | No | No | No | No | 1.19 | Low |
15 | Squalene | 9.38 | No | No | No | No | No | No | No | − 0.58 | Low |
16 | E,E,Z-1,3,12-Nonadecatriene-5,14-diol | 4.94 | Yes | Yes | Yes | No | Yes | Yes | Yes | − 4.08 | High |